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Abstract: Various types of toxic xenobiotic and electrophilic compounds, which were formed from 
the glutathione S-transferases cell metabolism and the oxidation stress, are the group enzymes with 
detoxification roles that are involved in the metabolism phase II. During the GSTM1 and GSTT1 gene 
homozygous deletion, the above enzymes completely lose their activity and consequently somatic 
mutation is formed. Furthermore, it is considered that it might have increased the risk of cancer. 
Therefore, the research works which connected the GSTMI and GSTTI gene deletion with the cancer 
of kidney, lung, prostate, breast, stomach, esophagus, large and narrow intestines. In this study, two 
gene deletion distribution is detected for cancer patients. We collected the blood samples of 60 
patients who have been diagnosed with cancer. The DNA was extracted and the GSTM1 and GSTT1 
genes were amplified using multiplex PCR. According to our research, the above two gene deletion 
is predominant among patients who have cancer. The results showed that from the total 60 patients 
GSTM1 and GSTT1 both deletions, GSTM1 gene deletion - 35%, GSTM1 gene deletion - 25%, GSTT1 
gene deletion - 26.7%, GSTM1 and GSTT1 both positive -13.3 %. Therefore, we think that in order 
to prevent tumor and cancer, these gene mutations must be revealed and it is important to bring the 
risky group under medical control and assist them in order to prevent them from this disease. 
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INTRODUCTION  
 
The number of the patients in Mongolia 
who have been diagnosed with cancer has been 
increasing from year to year and approximately 
about 4,000 people have died of cancer. People 
in Ulaanbaatar city and the rest of the country 
are living in quite a risky condition in as much 
as medicinal drug use is inappropriate and often 
times without prescription, and consume food 
with high level of food preservatives, which are 
tolerant to pesticides and herbicides etc. Food 
safety is not guaranteed in addition to high level 
of air and environment pollution.  
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One of the distinctive features of the 
human body is that it has the system to render 
harmless external-source toxic or dangerous 
combinations which are formed as a result of 
metabolism. One of them is GST or glutathione 
S-transferases, which are a family of 
ubiquitously expressed polymorphic enzymes 
that are involved in the metabolism phase II 
[13][9][7][5]. The main biological role of 
Glutathione S-transferases is to protect the cell 
membrane and DNA from damage owing to 
regular metabolism oxidation and detoxifying 
products, given that there are so many types of 
carcinogen and electrophilic compounds (such 
as ketones, quinones, sulfoxides, esters, 
peroxides, and ozonides), chemotherapeutics 
(such as busulfan, cis-platin, ethacrynic acid, 
cyclophosphamide, thiotepa) industrial 
chemicals herbicides, pesticides (acrolein, 
lindane, malathion, tridiphane) that are 
involved, directly and indirectly to render them 
harmless. Glutathione S-transferases is 
genetically determined as polymorphic. It is 
considered that several of the GST polymorphic 
participate in cancer development, medicine 
haul against cancer, and it influences its 
metabolism and also participate in the other 
diseases [2] [4][ 5][7][10][11][12] [14] [16]. 
The GST that exists in the human cell’s 
cytoplasm is divided into 8 classifications. 
From them, isoforms of GSTM1, GSTT1, and 
GSTP1 have been most commonly studied by 
researches. For the genotype, the GSTM1, 
GSTT1 become null. Therefore, the particular 
gene does not have the coded enzyme and thus 
becomes inactive or non-binding, which is why 
it is studied and researched with great attention 
[4][5][14][15]. In this study, we have tried to 
determine how the distribution of two gene 
deletion is detected. 
 
MATERIALS AND METHODS 
 
Samples: were taken from the outpatient 
clinic of the Mongolian National Cancer 
Center. Sample blood came from 60 patients 
who were diagnosed with cancer diagnosed, 
who had undergone surgical operations and 
those who were undergoing chemical and 
radiation treatment at the center’s out-patient 
clinic. Genomic DNA was isolated using the 
chloroform method.  
Apex. 2.0XTaq Red (1.5mM MgC12) 
Master mix kit was used. The reaction’s total 
volume – 20ul, 10ul of master mix, 1ul of each 
primer, 1.5ul of extracted DNA as template for 
gene amplification. The GSTM1 primers, (f: 
5’- GAA CTC CCT GAA AAG C-3’, r: 5’-
GTT GGG CTC AAA TAT ACG GTG G-3’) 
were used for the amplification of the 218 bp 
fragment. The primers of GSTT1 F: 5’- 
TTCCTTACTGGTCCTCACATCTC3’. R: 5’-
TCACCGGATCATGGCCAGCA-3’-were 
used for the amplification of the 480bp 
fragment. The cycling condition involved an 
initial pre-denaturation at 940C for 4 minutes, 
and followed by 32 cycles of PCR 
amplification. Amplification conditions were 
as follows: denaturation at 950C for 1 minute, 
primer annealing at 580C for 1 minute, and 
extension at 720C for 10 minutes. The final 
extension step at 720C for 6 minutes ended the 
process with the help of ArktikTM Thermal 
Cycler., Thermo fisher was increased. PCR 
amplicons were separated on 1.6% agarose gel 
and stained with ethidium bromide. Bands 
were visualized under UV light and GSTM1, 
GSTT1 bands were detected with the presence 
of bands 218bp and 480bp on the gel. The 
patients were grouped as either positive or null 
genotypes. 
 
RESULTS AND DISCUSSION 
 
For patients who have GSTT1, GSTM1 
and GSTP1 gene changes, have high 
probability of having cancers of the bladder, 
breast, large and narrow intestines, brain and 
lung. Therefore, in our study we involved 60 
cancer patients - 25 of them had liver cancer, 8 
- breast cancer, 5 - ovarium cancer, 5 - cervix of 
uterus cancer, 4 - rectum cancer, 4 - stomach 
cancer. Involved in our study were also cancer 
patients who had oral, lung, testicle, thyroid, 
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esophagus and prostate cancer. The sex ratio 
was 41 - female and 19 - male. In terms of age, 
they were aged between 32 and 76 years old.  
Another study, Ashton et al., 2007, found 
that GSTM1 null genotype is associated with 
high risk of neuroblastoma in Australia and 
New Zealand. It has been observed through 
research that children with GSTT1 gene 
deletion and AML-disease are more likely to 
die after chemical treatment [5]. Also in another 
research, during both the GSTT1, GSTM1 gene 
deletion, people who have the AML-disease 
have higher risk of becoming sick again after 
the treatment [4]. These gene deletion 
contribute to increase in rapture, allergy, 
atherosclerosis, and also partially prompts 
rheumatoid arthritis risk, therefore utmost care 
must be taken. According to published data, 
genetic diversity in the Japanese population 
shows slightly higher GSTM1 null genotype 
(55.8%) and significantly higher GSTT1 null 
genotype (40.0%) frequencies. The GSTM1 
and GSTT1 genotype frequencies of the control 
population in our study were in accordance with 
other reported frequencies. There is yet another 
research which revealed that 75% (highest) of 
the Caucasian citizens have the GSTM1 gene 
deletion [16] from other genotype. According 
in this study, which covered a total of 60 
patients, GSTM1 and GSTT1 both deletions 
and GSTM1 gene deletion was 35%, GSTM1 
gene deletion was 25%, GSTT1 gene deletion 
was 26.7%, GSTM1 and GSTT1 both without 
deletion was 13.3 %. 
 
 
Figure 1. GSTM1 and GSTT1 gene deletion indication among cancer patients 
 
In the event if there is both GSTM1 and 
GSTT1 gene deletion, and when either one of 
them is compared, then GSTM1 and GSTT1 
gene deletion was higher for patients aged 32 to 
50. In our research, it was observed that there 
are quite a substantial number of cancer patients 
in Mongolia, have both the GSTM1 and GSTT1 
gene deletion. Either GSTM1 and GSTT1 gene 
without-deletion or positive version was 
revealed in 8 patients, who had ovarium, 
thyroid, rectum and liver tumor. 
When considering a combination of 
alleles of the GSTT1 and GSTM1 genes, the 
proportion of deletated alleles of both genes in 
patients was slightly higher (35%) than in the 
separate GSTT1 - 25%, GSTM1 - 26.6% 
(Table1), whereas the frequency of both alleles 
without deletions is 13.3% (Figure 3).  
 
Table 1. Distribution of GSTM1, GSTT1 genotypes in the study groups 
 
Gene Deletion % n 
GSTM1 26.6 16 
GSTT1 35 21 
GSTM1 
GSTT1 25 15 
 Vol. 59 No 04 (232) 2019 
DOI: https://doi.org/10.5564/pmas.v59i4.1293 
 
25 
 
 Proceedings of the Mongolian Academy of Sciences 
PMAS 
 
Figure 3. GSTM1 and GSTT1 gene deletion in different cancer patients  
 
 
Figure 4: Multiplex PCR result (with number 1,8,11 – GSTT1/480bp/ positive., 3,6,7,8,9,10 numbers – 
GSTM1 /218/ positive., 2,4,5 – GSTM1, GSTT1 gene both have the deletion, number 8 – GSTM1 and GSTT 
gene both positive, N - negative control)
 
A different multiple case-controlled 
studies revealed statistically significant 
associations of the GSTM1 null genotype with 
increased risk of childhood cancers.  
Research groups from different regions in 
the world found that GSTM1 null genotype is 
related to increased risk of acute leukemia 
(ALL and ALP) in various populations. 
CONCLUSIONS 
 
Cancer is a multifactorial disease, one of 
which is hereditary predisposition and the 
surrounding environment. Our work for the first 
time shows that the increased risk of cancer 
among Mongolian cancer patients may be 
associated with the zero genotype of the 
GSTM1, GSTT1 genes. According to our 
research, the above two gene deletion is 
predominant among patients who have fallen ill 
dues to cancer (86.6%). Therefore, we think 
that in order to prevent from tumor and cancer, 
these gene mutation needs to be revealed and 
the risk groups must be taken under medical 
control and they must be given assistance in 
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preventing this disease.  
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